cbcaaaeb

Mike Benson

Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.

More From Mike Benson

  • uploads///Article
    Company & Industry Overviews

    How Did AstraZeneca’s CVMD Franchise Perform in 2014?

    In 2014, AstraZeneca’s CVMD franchise generated nearly $9.8 billion, a 11% rise in sales as compared to $8.8 billion in 2013.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Major Developments for Eli Lilly and Co. in 4Q15

    Eli Lilly and Co.’s (LLY) 4Q15 segment-wise performance was positive for both its Human Pharmaceuticals and Animal Health segments.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Merck & Co.’s Animal Health Segment

    The revenues of Merck & Co.’s Animal Health segment have improved due to increased sales in the Companion Animal Products segment.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Major Developments for Johnson & Johnson in 3Q16

    Major developments As discussed previously in this series, Johnson & Johnson’s (JNJ) 3Q16 performance was positive across all of its segments. However, the Consumer segment reported a decline in revenue, as the negative impact of foreign exchange more than offset operational growth. There were several major developments for JNJ during 3Q16. Pharmaceuticals segment In 3Q16, the […]

    By Mike Benson
  • uploads///Pharma
    Earnings Report

    Johnson & Johnson’s Pharmaceuticals Segment Grows in 2Q15

    Johnson & Johnson’s (JNJ) Pharmaceuticals segment grew by 1.0% at constant exchange rates, reporting a revenue of $7,946 million for 2Q15 over 2Q14.

    By Mike Benson
  • uploads///Chart  AR
    Earnings Report

    Analysts’ Ratings and Recommendations for Johnson & Johnson

    JNJ’s stock price has increased nearly 16.2% in the last 12 months and nearly 18.6% year-to-date.

    By Mike Benson
  • uploads///pill _
    Company & Industry Overviews

    GlaxoSmithKline’s Valuation on June 29

    In the first quarter, GlaxoSmithKline reported EPS of 24.60 pence on revenue of 7.2 billion pounds, a 2% fall year-over-year.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    How Did JNJ’s Pharmaceuticals Segment Perform in 4Q16?

    Johnson & Johnson’s (JNJ) pharmaceuticals segment consists of its immunology, infectious disease, neuroscience, oncology, and cardiovascular and metabolics franchises.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Pfizer’s Quarterly Revenue Trend in Q2 2018

    Pfizer (PFE) reports its revenue into two business segments: Innovative Health and Essential Health.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    The Latest Recommendations for Incyte

    Wall Street analysts expect Incyte (INCY) to report a 17.8% YoY (year-over-year) rise in sales to $1.81 billion in 2018.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Eli Lilly’s 1Q18 Earnings by Segment

    Eli Lilly’s (LLY) products are classified into two business segments: Human Pharmaceutical Products and Animal Health Products.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What Analysts Recommend for Novartis in March 2018

    As discussed earlier, Novartis (NVS) reported EPS (earnings per share) of $1.21 on revenues of $12.9 billion during 4Q17.

    By Mike Benson
  • uploads///Chart  NMDA
    Company & Industry Overviews

    What Are Sage Therapeutics’ Receptor-Based Products?

    Sage Therapeutics (SAGE) is focused on the development of the products for the treatment of life-threatening central nervous system (or CNS) disorders.

    By Mike Benson
  • uploads///Article
    Company & Industry Overviews

    AstraZeneca’s ING Franchise Saw Lower Revenues in 2014

    For 2014, AstraZeneca’s ING franchise generated nearly $8.2 billion, a 8.9% decrease as compared to $9.0 billion in 2013.

    By Mike Benson
  • uploads///Chart  Animal
    Company & Industry Overviews

    This Is Eli Lilly’s Animal Health Segment

    Eli Lilly’s (LLY) Animal Health segment company, Elanco, reported a 9% YoY fall in revenues at $706 million in 3Q16, as compared to $779 million in 3Q15.

    By Mike Benson
  • uploads///Chart  Revenues
    Earnings Report

    Johnson & Johnson’s 3Q17 Revenue Estimates Could Reveal Growth

    Johnson & Johnson’s (JNJ) revenues are expected to report 8.3% growth to $19.3 billion during 3Q17.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at Johnson & Johnson’s Post-2Q17 Valuation

    Headquartered in New Jersey, Johnson & Johnson (JNJ) is one of the largest pharmaceutical companies, with its products sold in over 200 countries worldwide. This series will look at how it has performed since its 2Q17 earnings announcement.

    By Mike Benson
  • uploads///Article
    Company & Industry Overviews

    Lilly’s Total Returns Are Lower than Some Pharma ETFs

    The total return for Lilly’s share price on the NYSE from July 2010 to June 2015 has been around 17.9%. This is lower than a few of the pharmaceutical ETFs.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    A Look at Ionis’s Revenue Streams in the Second Quarter

    Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to the revenues of $112 million during the second quarter of 2017.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Johnson & Johnson’s Valuation Cheat Sheet

    On January 26, 2017, the company was trading at a forward PE of ~15.8x. Based on the last five years’ multiple range, JNJ’s current valuation is neither high nor low.

    By Mike Benson
  • uploads///Article
    Company & Industry Overviews

    Sanofi Increased Net Revenues in 2014

    Sanofi’s net revenues increased by ~2.5% to 33.8 billion euros in 2014, as compared to $23.2 billion in 2013.

    By Mike Benson
  • uploads///Article
    Earnings Report

    Novartis’s Adjusted Earnings per Share Declined 7% in 2Q15

    Novartis (NVS) posted its 2Q15 earnings on July 21, 2015. The company achieved adjusted EPS of $1.27 for 2Q15, ~7% lower than in 2Q14.

    By Mike Benson
  • uploads///blood _
    Healthcare

    Johnson & Johnson Stock on March 29, 2018

    Although Johnson & Johnson stock has fallen ~3.5% in the last month, its stock has risen ~1.4% in the last year.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Analysts’ Estimates and Ratings for Novartis in October

    Novartis’s revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.

    By Mike Benson
  • uploads///Chart
    Miscellaneous

    Squire Study Supports Portrazza’s Approval

    The FDA approved Portrazza for the treatment of squamous NSCLC based on the results of a phase III study named Squire.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    MedMen’s Territory Expansion: The Recent Agreements

    MedMen (MMNFF) has entered into agreements with different companies to expand its footprint. We outline a few of the recent agreements below.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What Analysts Project for Eli Lilly in 3Q17

    For 3Q17, analysts estimate that Eli Lilly will post EPS of $1.03 on revenues of $5.5 billion.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Why the Majority of Analysts Deem Novartis a ‘Buy’

    Novartis met Wall Street analysts’ estimates for EPS (earnings per share) in 4Q16, reporting EPS of $1.12 as estimated but missing revenue estimates.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    How Analysts View Allergan after Its 1Q18 Earnings

    Allergan (AGN) surpassed Wall Street analysts’ estimates, reporting earnings per share of $3.74 on revenues of $3.7 billion during 1Q18.

    By Mike Benson
  • uploads///health
    Company & Industry Overviews

    Johnson & Johnson’s Valuation in February 2018

    Johnson & Johnson (JNJ) reported revenues of $20.2 billion in 4Q17, an 11.5% growth compared to 4Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What Does the Future Hold for Seattle Genetics?

    Seattle Genetics has surpassed all estimates for earnings per share in the past.

    By Mike Benson
  • uploads///thermometer _
    Company & Industry Overviews

    A Look at Allergan’s Valuation on August 16

    In this series, we’ll discuss Allergan’s valuation, segment and product performances, recent developments, and analyst recommendations.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Understanding Sanofi’s 3Q17 Performance by Business Segment

    Sanofi now reports its business in two segments: Human Pharmaceuticals and Sanofi Pasteur (or the Human Vaccines segment).

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analysts’ Recommendations for Merck & Co. after 4Q17

    Merck & Co. (MRK) missed Wall Street analysts’ estimates for revenues but surpassed analysts’ estimates earnings per share.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Bristol-Myers Squibb Continues Revenue Growth in 3Q16

    Bristol-Myers Squibb (BMY) reported a growth of 21% to $4.9 billion in its 3Q16 results.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What Does Johnson & Johnson Predict for Its Medical Devices Segment?

    Johnson & Johnson’s (JNJ) medical devices segment deals with vision care, cardiovascular care, specialty surgery, orthopedics, surgical care, and diabetes care.

    By Mike Benson
  • uploads///Chart  PFE
    Company & Industry Overviews

    A Closer Look at Pfizer Stock in 1Q18

    Pfizer’s stock price has fallen ~3.5% in 1Q18, while its stock price has fallen ~2.9% YTD (year-to-date) as of April 6, 2018.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What Did AGN’s US Medical Aesthetics Segment Contribute in 1Q16?

    Allergan’s US medical aesthetics segment includes facial aesthetics, medical dermatology products, and a wide range of silicone and saline breast implants.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Merck’s Valuation Cheat Sheet for Fiscal 1Q16

    Merck & Co.’s (MRK) current valuation is neither high nor low. Its valuation multiple has followed the industry’s overall trend over the last five years.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analysts’ Estimates and Recommendations for Allergan on July 19

    Analysts expect Allergan’s second-quarter revenue to fall ~2.5% to $3.9 million compared to its revenue of $4.0 million in the second quarter of 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Allergan’s International Business Segment

    Allergan’s International Business segment reported revenue of $864 million during the first quarter.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Pfizer’s 1Q16 Earnings: Products That Saw Sales Drop

    The overall share of revenue for Pfizer’s Established Products segment decreased to 44.6% in 1Q16 from 48.8% for 1Q15.

    By Mike Benson
  • uploads///ccdafbcfbddefdffcb
    Company & Industry Overviews

    Market Response to EMA Validation of Opdivo Application

    BMY has four key oncology products, including Erbitux, Opdivo, Sprycel, and Yervoy. Two of these contributed more than $1 billion in 2014.

    By Mike Benson
  • uploads///Article
    Company & Industry Overviews

    How Did Sanofi’s Merial Segment Perform in 2014?

    The contribution of Merial, the animal health arm of Sanofi (SNY), was ~6.0%, or ~2.1 billion euros, towards the company’s total revenues in 2014.

    By Mike Benson
  • uploads///Chart  RevEPS
    Company & Industry Overviews

    Eli Lilly’s Valuation in December 2017

    Eli Lilly (LLY) surpassed analysts’ estimates for EPS and revenues and reported EPS of $1.05 on revenues of $5.7 billion in 3Q17.

    By Mike Benson
  • uploads///chart_
    Company & Industry Overviews

    Recent Developments for Ionis Pharmaceuticals

    On March 6, 2017, Ionis and Akcea announced positive results from the Phase III study APPROACH, evaluating volanesorsen for the treatment of patients with FCS.

    By Mike Benson
  • uploads///Chart  USST
    Earnings Report

    Behind Allergan’s US Specialized Therapeutics Segment in 1Q17

    In 1Q17, Allergan’s US Specialized Therapeutics segment revenues rose 14.1% to $1.48 billion, as compared to $1.30 billion in 1Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    GlaxoSmithKline’s Quarterly Revenue Trend in 4Q17

    GlaxoSmithKline (GSK) reported revenues of 7.64 billion pounds in 4Q17, a ~1% growth compared to 7.59 billion pounds in 4Q16.

    By Mike Benson
  • uploads///close up _
    Earnings Report

    Pfizer Missed Analysts’ Third-Quarter Revenue Estimates

    Pfizer (PFE) released its third-quarter earnings on October 30.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Does Allergan’s Financial Guidance Look for 2016?

    Allergan (AGN) estimates that its revenues will be around $17 billion in 2016.

    By Mike Benson
  • uploads///Chart  Revenues
    Earnings Report

    Johnson & Johnson’s 4Q15 Estimates: Revenues Will Fall

    On an annual basis, Johnson & Johnson’s revenues have increased over the past few years following the restructuring of its business segments and strong performance of some of its key products.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Understanding the Revenue Fall in AstraZeneca’s Largest Segment in 3Q16

    AstraZeneca’s (AZN) CVMD (Cardiovascular and Metabolic Disease) segment contributed nearly 32.4% of total company revenues in 3Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What’s Driving Pfizer’s Revenue?

    Pfizer has divided its product portfolio into two segments: Innovative Health and Essential Health. It reports revenue for both these segments.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Merck Is Getting Serious about Animal Health

    Merck’s (MRK) Animal Health segment operates in more than 140 countries worldwide. The global sales reported for 3Q16 totaled ~$865 million.

    By Mike Benson
  • uploads///Costs
    Earnings Report

    Bristol-Myers Squibb’s Profitability and Financial Guidance

    Bristol-Myers Squibb estimates that its revenues will be between $15.5 billion and $15.9 billion, which is nearly flat as compared to 2014 revenues of $15.9 billion.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Pfizer’s 1Q16: A Valuation Cheat Sheet

    On March 28, 2016, Pfizer was trading at a forward price-to-earnings multiple of ~12.9x.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What Does AstraZeneca’s Growth Platform Offer?

    The RI&A (respiratory, inflammation and autoimmunity) segment one of the company’s growth platforms, is a key area of development for AstraZeneca (AZN).

    By Mike Benson
  • uploads///Chart  Product
    Earnings Report

    Pfizer’s Key Product Developments in 1Q17

    To strengthen the innovative health business, the company is focusing on the development of new drugs as well as expanding the market reach of existing products.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Merck’s Gardasil and What It Could Mean

    Total sales from Merck’s Gardasil during 3Q16 reached $860 million, a rise of ~38% over the $625 million in 3Q15.

    By Mike Benson
  • uploads///syringe _
    Company & Industry Overviews

    Assessing Novartis’s Performance in October So Far

    Novartis’s ADR (American depositary receipt) has fallen ~1.0% to date in October, while it’s risen nearly 3.3% in the last month.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Analysts Give Mixed Recommendations for Novartis

    Novartis’s stock price has fallen ~7.0% in the last 12 months and ~10.7% year-to-date.

    By Mike Benson
  • uploads///Chart  Revenues
    Company & Industry Overviews

    A Look Back at Eli Lilly’s 2016 Revenue Trends

    Eli Lilly (LLY) reported a ~6% rise in its revenue to $21.2 billion in 2016, compared to its revenue of $20.0 billion in 2015.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What Do Analysts Recommend for Pfizer?

    Pfizer reported EPS of $0.67 on revenue of $13.0 billion in 1Q16 against the estimated $0.56 on revenue of $12.1 billion in 1Q16.

    By Mike Benson
  • uploads///Chart  Cardiovascular
    Earnings Report

    How Eli Lilly’s Cardiovascular Franchise Performed in 1Q16

    Eli Lilly’s (LLY) cardiovascular franchise contributed ~15.5% of the company’s total revenues in 1Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    AstraZeneca’s Other Products in 3Q16

    With lower sales from blockbuster drugs Nexium and Seroquel, the contribution of AstraZeneca’s (AZN) Other segment fell to ~21.2% in 3Q16.

    By Mike Benson
  • uploads///Chart  Gardasil
    Company & Industry Overviews

    Merck’s Gardasil and Other Human Vaccines in 3Q17

    Merck & Co.’s (MRK) Gardasil franchise reported total sales of $675 million in3Q17, a 22% fall compared to $860 million in 3Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Seattle Genetics’ 1Q16 Earnings: What Are Analysts Expecting?

    Seattle Genetics is set to release its first-quarter 2016 earnings on April 28, 2016. Analysts estimate revenues of around $116 million for 1Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Merck’s Post-1Q18 Valuation

    In 1Q18, Merck’s revenue grew 6% YoY (year-over-year) to $10.0 billion from $9.4 billion, and its EPS (earning per share) rose to $1.05 from $0.88.

    By Mike Benson
  • uploads///syringe _
    Earnings Report

    AstraZeneca’s 1Q18 Earnings: Analysts’ Estimates

    AstraZeneca (AZN) is one of the leading pharmaceutical companies that deals with primary care and specialty care products.

    By Mike Benson
  • uploads///microbiology _
    Earnings Report

    Expectations from Novartis’s 1Q18 Earnings

    Novartis is set to release its 1Q18 earnings on April 19, 2018. Analysts expect it to report earnings per share of $1.28.

    By Mike Benson
  • uploads///cannabis _
    Company & Industry Overviews

    WeedMD Secures Cannabis Sales License from Health Canada

    On November 13, WeedMD announced that Health Canada approved its cannabis sales license for cannabis cultivated at its greenhouse in Ontario.

    By Mike Benson
  • uploads///tablets _
    Earnings Report

    Johnson & Johnson’s Revenues Continued to Rise in 1Q18

    Johnson & Johnson surpassed Wall Street analysts’ estimates for EPS (or earnings-per-share) and revenues in 1Q18.

    By Mike Benson
  • uploads///medic _
    Company & Industry Overviews

    Analyzing Merck’s Revenue in 1Q18

    Merck (MRK), one of the largest pharmaceutical companies worldwide, reported its 1Q18 results on May 1.

    By Mike Benson
  • uploads///Chart  MRK
    Company & Industry Overviews

    How Merck & Co. Stock Performed in 1Q18

    Merck & Co. stock has fallen ~6.4% in 1Q18, while it’s fallen ~5.2% YTD (year-to-date) as of April 6, 2018.

    By Mike Benson
  • uploads///Chart
    Healthcare

    Novartis’s Stock Performance following the AveXis Agreement

    Novartis AG (NVS) announced an agreement and plan for a merger with AveXis on April 9, 2018.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    A Look at Incyte’s Valuation as of May 25

    Incyte reported EPS of -$0.19 on revenue of $382.3 million in Q1 2018 compared to revenue of $384.1 million in Q1 2017.

    By Mike Benson
  • uploads///dna _
    Healthcare

    Amgen Stock Rises over 2% on Drug Approvals

    Amgen (AMGN) stock has risen ~2.3% in the last week following recent drug approvals.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Decoding Humana’s Revenue Stream in 2015

    Humana reported revenues of about $54.3 billion in its 2015 results. This amounts to a 12% revenue growth in 2015, compared to ~$48.1 billion in 2014.

    By Mike Benson
  • uploads///Chart  CELG
    Company & Industry Overviews

    Celgene Stock Performance in 1Q18

    Wall Street analysts estimate that Celgene (CELG) stock has the potential to return 31.6% over the next 12 months.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca and Its Oncology Segment’s Growth in 2Q16

    AstraZeneca’s (AZN) oncology segment is another key focus area. The segment’s contribution increased to more than 15% in 2Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What’s to Be Expected from Novartis’s 3Q16 Earnings?

    Novartis, one of the world’s largest pharmaceutical companies by revenue, is set to release its 3Q16 earnings on October 25, 2016.

    By Mike Benson
  • uploads///Growth
    Earnings Report

    Johnson & Johnson’s 3Q15 Changes in Growth Rate

    Foreign exchange rates seem to have had a negative impact on Johnson & Johnson’s growth rate since ~50% of total revenues are reported from sales outside the US.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What’s Johnson & Johnson’s Valuation after 1Q18 Earnings?

    The price-to-earnings (or PE) multiple represents what one share can buy an equity investor.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Merck’s Animal Health Segment Did in 1Q18

    In 1Q18, Merck’s (MRK) Animal Health segment, which includes drugs and vaccines for animals, saw its revenue grow 13% YoY (year-over-year) to ~$1.1 billion from $939 million.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What Drove Ionis’s Revenue in Q1

    In the first quarter, leading biopharmaceutical company Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million.

    By Mike Benson
  • uploads///virus infected cells _
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Valuation on May 23

    Ionis Pharmaceuticals (IONS), a leading therapeutics company, develops and markets drugs for life-threatening diseases.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What Analysts Think about Ionis

    In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What to Expect from Pfizer’s 2Q16 Earnings

    In Pfizer’s 2Q16 results, analysts expect to see EPS (or earnings-per-share) of $0.62 and revenues of ~$13.0 billion for 2Q16. The company has surpassed Wall Street analysts’ estimates for EPS over the last few quarters.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Allergan’s Business Segments in 1Q18

    Allergan’s US Specialized Therapeutics business revenues rose 6.5% to $1.6 billion during 1Q18, compared to $1.5 billion during 1Q17.

    By Mike Benson
  • uploads///Chart  AZN
    Company & Industry Overviews

    How AstraZeneca’s 1Q18 Shook Out

    AstraZeneca stock has fallen ~1.2% in 1Q18, and its stock has risen ~2.1% YTD (year-to-date) as of April 6, 2018.

    By Mike Benson
  • uploads///pill _
    Earnings Report

    What Do Analysts Predict for Bristol-Myers Squibb in 1Q18?

    Analysts estimate Bristol-Myers Squibb will post EPS of $0.85 and revenues of $5.2 billion for 1Q18.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Bristol-Myers Squibb’s 2Q16 Estimates: Other Segments

    Bristol-Myers Squibb’s (BMY) neuroscience segment is represented by the drug Abilify, while its immuno-science segment is represented by the drug Orencia.

    By Mike Benson
  • uploads///joshua coleman  unsplash
    Company & Industry Overviews

    Pfizer Expands Its Investment Portfolio through Pfizer Ventures

    On June 6, Pfizer announced that it would invest ~$600 million in biotechnology and emerging growth companies through Pfizer Ventures.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Mylan’s Recent Commercial and Product Developments

    Mylan’s recent commercial developments include the acquisition of the Cold-EEZE brand from ProPhase Labs and the acquisition of Meda AB.

    By Mike Benson
  • uploads///headache _
    Earnings Report

    What Analysts Predict for GlaxoSmithKline’s 1Q18 Earnings

    GlaxoSmithKline is set to release its 1Q18 earnings on April 25, 2018.

    By Mike Benson
  • uploads///ousa chea  unsplash
    Healthcare

    BlueBird Bio Stock Jumps over 6% on May 17

    BlueBird Bio stock has risen ~119.9% over the last 12 months and 6.3% year-to-date.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Novartis’s 1Q16 Earnings Got a Neutral Response from Investors

    Novartis (NVS) released its 1Q16 earnings on April 21, 2016. It reported top-line growth of 1% at constant exchange rates for 1Q16—compared to 1Q15.

    By Mike Benson
  • uploads///Chart  AGN
    Company & Industry Overviews

    Allergan Stock Performance in 1Q18

    Wall Street analysts estimate that AGN stock has the potential to return 33.7% over the next 12 months.

    By Mike Benson
  • uploads///freestocks org  unsplash
    Company & Industry Overviews

    Merck and AstraZeneca Announced EMA Approval for Lynparza

    Lynparza (olaparib) is a poly(ADP-ribose) polymerase inhibitor, or PARP inhibitor, and part of Merck & Co. (MRK) and AstraZeneca’s (AZN) global strategic oncology collaboration.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Eli Lilly’s Neuroscience Products Sales Dropped in Q2 2018

    Zyprexa reported revenues of $128.0 million in Q2 2018, a 9.0% decline in YoY revenues compared to $140.8 million in Q2 2017.

    By Mike Benson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.